Inhibition of GSK-3 prevents p100 degradation and allows for p100-mediated suppression of the noncanonical NF-κB pathway and myeloma cell death.26 These findings coupled with anti-tumor activity in models of several malignancies supported the clinical development of 9-ING-41 for treatment of solid organs and hematological malignancies. Here, NFKB1 is linked to plasma cell myeloma.